Literature DB >> 2433934

Fundamental mechanisms of action of calcium antagonists in myocardial ischemia.

W G Nayler, S Panagiotopoulos, J S Elz, W J Sturrock.   

Abstract

The mammalian myocardium exhibits a spectrum of damage during an ischemic episode. After relatively short periods of ischemia the damage is reversible, but with longer periods of ischemia the number of cells that are lethally injured increases. When coronary flow is restored the lethally injured cells become overloaded with Ca++ and fail to regenerate adenosine triphosphate. The calcium antagonists provide protection under these circumstances, but only if used prophylactically. When added only upon reperfusion the calcium antagonists slow, but do not inhibit, the excessive gain in Ca++ that occurs during postischemic reperfusion. Nicotine, in a concentration equivalent to that found in the plasma of smokers (0.15 microgram/ml), exacerbates the reperfusion-induced Ca++ gain. Treatment with the long-acting calcium antagonist, anipamil, on a once-daily basis attenuates the reperfusion-induced Ca++ gain in spontaneously hypertensive rats and its exacerbation by nicotine in Sprague Dawley rats. The prolonged oral administration of at least 1 calcium antagonist, verapamil (50 mg/kg body weight/day), causes a significant (p less than 0.001) depletion of left ventricular norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433934     DOI: 10.1016/0002-9149(87)90086-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia.

Authors:  Q Timour; B Bui-Xuan; G Faucon; J F Aupetit
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 2.  Calcium antagonists: whither now?

Authors:  W G Nayler
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 3.  The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders.

Authors:  W G Nayler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Effect of D-600 on ischemic and reperfused rabbit myocardium: relation with timing and modality of administration.

Authors:  R Ferrari; G M Boffa; C Ceconi; S Curello; A Boraso; S Ghielmi; A Cargnoni
Journal:  Basic Res Cardiol       Date:  1989 Nov-Dec       Impact factor: 17.165

5.  Effect of gallopamil on myocardial ischaemia during percutaneous transluminal coronary angioplasty.

Authors:  B Rauch; J Neumann; G Richardt; R Kranzhöfer; R Barth; R Zimmermann; H P Koch; H Tillmanns; A Schömig
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6.  Moderation of myocardial ischemia reperfusion injury by calcium channel and calmodulin receptor inhibition.

Authors:  Y Kimura; R M Engelman; J Rousou; J Flack; J Iyengar; D K Das
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

Review 7.  Calcium antagonists and stunned myocardium: importance for clinicians?

Authors:  K Przyklenk; R A Kloner
Journal:  Cardiovasc Drugs Ther       Date:  1991-10       Impact factor: 3.727

Review 8.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

9.  Inhibitory effects of calcium antagonists on mitochondrial swelling induced by lipid peroxidation or arachidonic acid in the rat brain in vitro.

Authors:  M Takei; M Hiramatsu; A Mori
Journal:  Neurochem Res       Date:  1994-09       Impact factor: 3.996

10.  Effect of lacidipine on ischaemic and reperfused isolated rabbit hearts.

Authors:  A Boraso; A Cargnoni; L Comini; G Gaia; P Bernocchi; R Ferrari
Journal:  Mol Cell Biochem       Date:  1993-08-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.